Trials / Completed
CompletedNCT00718562
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
A Multi-center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of nilotinib in gastrointestinal stromal tumors patients who failed imatinib and sunitinib therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMN107 |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2008-07-18
- Last updated
- 2017-02-23
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00718562. Inclusion in this directory is not an endorsement.